SCHEMBL5224736

SCHEMBL5224736

CC(C)(C)c1ccc(C(=O)c2cccc(N)c2NC(=O)c2ccc(F)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.55
KDM4E B2RXH2 1/20 0.50
HDAC1 Q13547 3/20 0.49
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
XBP1 P17861 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
TP53 P04637 1/20 0.44
THRB P10828 1/20 0.44
KCNK9 Q9NPC2 1/20 0.44
TRPV1 Q8NER1 2/20 0.44
GAA P10253 1/20 0.43
KCNK3 O14649 1/20 0.43
PPARG P37231 2/20 0.43
NR1H4 Q96RI1 2/20 0.43
BRAF P15056 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5228003 0.90 EPHX2 (0.48) MAPTHDAC1MEN1KMT2ASMN1; SMN2
SCHEMBL5226770 0.89 NR1H4 (0.46) MAPTHDAC1SMN1; SMN2NPC1RAB9A
SCHEMBL5226646 0.88 NPC1 (0.56) HDAC1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL5222203 0.86 MAPT (0.54) MAPTKDM4EHDAC1MEN1KMT2A
SCHEMBL5226616 0.84 KCNK9 (0.49) MAPTKDM4EHDAC1MEN1KMT2A
SCHEMBL5226258 0.84 KCNK9 (0.49) HDAC1MEN1KMT2ASMN1; SMN2TP53
SCHEMBL5225558 0.84 NPC1 (0.55) MAPTHDAC1MEN1KMT2ASMN1; SMN2
SCHEMBL5222596 0.83 KCNK9 (0.48) MAPTHDAC1MEN1KMT2ASMN1; SMN2
SCHEMBL5227852 0.82 KCNK3 (0.46) MAPTHDAC1MEN1KMT2ASMN1; SMN2
SCHEMBL7250538 0.81 TP53 (0.49) MAPTHDAC1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 MAPT 4291/4885KDM4E 2237/4885HDAC1 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.